Triple Negative Local Advanced Breast CancerNCT01216124
Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
A study testing docetaxel oxaliplatin in people with Triple Negative Local Advanced Breast Cancer, run by Fudan University.
Trial summary
The 10%-15% of breast carcinomas known to be 'triple negative (TN)' (not expressing HRs and not exhibiting overexpression Her2) constitutes 85% of all basal-like tumors, because it is based on three standard immunohistochemical biomarkers. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Triple Negative Local Advanced Breast Cancer
- What is being tested?
- docetaxel oxaliplatin
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- Adult, Older adult
Who may be able to join
- Women aged from 18 to 65 years;
- Histologically or cytologically proven invasive unilateral breast cancer (regardless of the type);
- Initial clinical condition compatible with complete initial resection;
- No residual macro or microscopic tumor after surgical excision;
- Patient presenting one of the following criteria (reviewed before randomization by referent pathologist):
- Triple Negative(ER-PR-Her-2-) Hormone receptor negativity is defined as ER<10%, PR<10% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH negative].
Show all 15Show fewer
- No clinically or radiologically detectable metastases (M0);
- No peripheral neuropathy > 1;
- WHO Performance status (ECOG) of 0 or 1;
- Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin > 9 g/dl);
- Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN,total bilirubin £ 1,5 ULN;
- Adequate renal function: serum creatinine £ 1.5 ULN;
- Patients accepting contraception intake during the overall length of treatment if of childbearing potential;
- Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography;
- Signed written informed consent.
Who cannot join
- Bilateral breast cancer or patient with controlateral DCIS;
- Any metastatic impairment, including homolateral sub-clavicular node involvement,regardless of its type;
- Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);
- Luminal A, Luminal B and Her-2 overexpression
- Any clinically or radiologically suspect and non-explored damage to the controlateral breast;
- Previous cancer (excepted cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive controlateral breast cancer;
Show all 13Show fewer
- Patients already included in another therapeutic trial involving an experimental drug;
- Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study;
- LEVF < 50% (MUGA scan or echocardiography);
- Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to randomization;
- Known prior severe hypersensitivity reactions to agents in this study
- Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 8 weeks after treatment completion;
- 14) Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase; 15) Women with a positive pregnancy test en enrollment or prior to study drug administration; 16) Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial; 17) Individual deprived of liberty or placed under the authority of a tutor.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: A Prospective, Open and Unicentric Phase II Clinical Trial of Docetaxel Combined With Oxaliplatin for Triple Negative Local Advanced Breast Cancer Patients (TNLABC)
The 10%-15% of breast carcinomas known to be 'triple negative (TN)' (not expressing HRs and not exhibiting overexpression Her2) constitutes 85% of all basal-like tumors, because it is based on three standard immunohistochemical biomarkers.
In clinical routine, Docetaxel was widely indicated as first-line therapy for breast cancer patients in adjuvant or neoadjuvant settings. Oxaliplatin, trans-1-diaminocyclohexane-platinum, may offer advantages over other platinum agents. Oxaliplatin promotes formation of DNA adducts, preventing DNA replication and transcription and ultimately causing apoptosis. Oxaliplatin was more potent than cisplatin and the Oxaliplatin-based regimen was active for the patients of lung cancer, colorectal cancer and ect. TNBC patients were more sensitive to platinum-based chemotherapy regimens according to the results of some retrospective studies. There was no report about Oxaliplatin in the chemotherapy setting for breast cancer patients.
The investigators hypothesized that using Oxaliplatin adding to docetaxel would be feasible and active in patients with TNLABC because in vitro findings suggest synergism between the agents. This study was designed to investigate the efficacy and toxicity of oxaliplatin-based regimen as a neoadjuvant chemotherapy setting in triple negative local advanced breast cancer patients
Read the detailed description
Eligibilty Female adults(>18 years old) were eligible if they had histologically or cytologically confirmed stage IIIb or IIIc TNLABC that had not been treated with any systemic treatment. Patients also had Eastern Cooperative Oncology Group(ECOG) Performance status of 0 or 1, absolute neutrophil count (ANC)>1500/mm3,hemoglobin >8.0g/dL, and platelet count >100,000/mm3,creatinine<2.5 times the upper limit of normal(ULN)）, transaminases<2.5 times ULN or alkaline phosphatase<4 times ULN if transaminases was normal, and total bilirubin <2.5 times ULN. Exclusion criteria were active infection, pregnancy, other primary malignancy (except in situ carcinoma of cervix or adequately treated nonmelanomatous carcinoma of the skin), any documented distant metastasis and uncontrolled systemic diseases.
This study protocol was approved by institutional ethic review boards and conducted according to guidelines for good clinical practice and the Helsinki Declaration.All patients provided written informed consent.
Study design and treatment plan This was a prospective, open and unicentric phase II clinical study. All chemotherpy was administered intravenously on an outpatient basis. The patients received dexamethasone 7.5mg orally twice a day for 3 days before the day of chemotherapy. On day 1, docetaxel 75mg/m2 was infused over 60 minutes as well as oxaliplatin 130mg/m2 was infused over 120 minutes on day 2. Thirty minutes before chemotherapy, premedication consisted of a 5-hydroxytryptamine3(HT3) receptor antagonist. Furthermore, Vitamin C 2g and Vitamin B2 200mg were followed immediately after the chemotherapy. Treatment was administered every 21 days for a maximum of four cycles or until disease progression or unacceptable toxicity.The prophylactic use of a colony-stimulating factor (CFS) was not permitted in the first cycle.
An initial diagnosis of unilateral primary breast cancer without distant metastases, at least 7 months of follow-up information for disease recurrence and death and triple receptor negative for estrogen receptor (ER), progesterone receptor (PR), Her2 were included as pre-treatment evaluation. Moreover tumor size, number of involved axillary lymph nodes (ALN), clinical stage and biomarkers such as Cathepsin-D, P53, nm23, PS2 and PCNA, were recorded as available information for further analysis. In the procedure of neoadjuvant chemotherapy, weekly or biweekly complete blood cell counts, physical examination, electrocardiogram (EKG), liver and rental function tests should be repeated. Tumor size was assessed by magnetic resonance imaging (MRI) every two cycles or when the clinical signs suggested disease progression as well as before the chemotherapy. Tumor response was determined by response evaluation criteria in solid tumors (RECIST). Complete and partial response (CR and PR) should be confirmed on two assessments performed at least four weeks apart.
- Being tested
- docetaxel oxaliplatin
- Keywords
- triple negative local advanced breast cancer(TNLABC),neoadjuvant chemotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
docetaxel oxaliplatinDrug
docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2
1 cycle=21 days DO*6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2010 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Triple Negative Local Advanced Breast CancerStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Collaborators
- Chinese Anti-Cancer Association
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01216124
- Sponsor's protocol ID
- Fudan TNBC Neo CT
- Status last verified
- Sep 2009
- First submitted
- 6 Oct 2010
- Last updated
- 7 Oct 2010
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open and Unicentric Phase II Clinical Trial of Docetaxel Combined With Oxaliplatin for Triple Negative Local Advanced Breast Cancer Patients (TNLABC)
- ClinicalTrials.gov ID
- NCT01216124
- Acronym / sponsor ID
- Fudan TNBC Neo CT
- Keywords
- triple negative local advanced breast cancer(TNLABC),neoadjuvant chemotherapy
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Collaborators
- Chinese Anti-Cancer Association
- First posted
- 7 Oct 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The 10%-15% of breast carcinomas known to be 'triple negative (TN)' (not expressing HRs and not exhibiting overexpression Her2) constitutes 85% of all basal-like tumors, because it is based on three standard immunohistochemical biomarkers.
In clinical routine, Docetaxel was widely indicated as first-line therapy for breast cancer patients in adjuvant or neoadjuvant settings. Oxaliplatin, trans-1-diaminocyclohexane-platinum, may offer advantages over other platinum agents. Oxaliplatin promotes formation of DNA adducts, preventing DNA replication and transcription and ultimately causing apoptosis. Oxaliplatin was more potent than cisplatin and the Oxaliplatin-based regimen was active for the patients of lung cancer, colorectal cancer and ect. TNBC patients were more sensitive to platinum-based chemotherapy regimens according to the results of some retrospective studies. There was no report about Oxaliplatin in the chemotherapy setting for breast cancer patients.
The investigators hypothesized that using Oxaliplatin adding to docetaxel would be feasible and active in patients with TNLABC because in vitro findings suggest synergism between the agents. This study was designed to investigate the efficacy and toxicity of oxaliplatin-based regimen as a neoadjuvant chemotherapy setting in triple negative local advanced breast cancer patients
Detailed description
Eligibilty Female adults(>18 years old) were eligible if they had histologically or cytologically confirmed stage IIIb or IIIc TNLABC that had not been treated with any systemic treatment. Patients also had Eastern Cooperative Oncology Group(ECOG) Performance status of 0 or 1, absolute neutrophil count (ANC)>1500/mm3,hemoglobin >8.0g/dL, and platelet count >100,000/mm3,creatinine<2.5 times the upper limit of normal(ULN)）, transaminases<2.5 times ULN or alkaline phosphatase<4 times ULN if transaminases was normal, and total bilirubin <2.5 times ULN. Exclusion criteria were active infection, pregnancy, other primary malignancy (except in situ carcinoma of cervix or adequately treated nonmelanomatous carcinoma of the skin), any documented distant metastasis and uncontrolled systemic diseases.
This study protocol was approved by institutional ethic review boards and conducted according to guidelines for good clinical practice and the Helsinki Declaration.All patients provided written informed consent.
Study design and treatment plan This was a prospective, open and unicentric phase II clinical study. All chemotherpy was administered intravenously on an outpatient basis. The patients received dexamethasone 7.5mg orally twice a day for 3 days before the day of chemotherapy. On day 1, docetaxel 75mg/m2 was infused over 60 minutes as well as oxaliplatin 130mg/m2 was infused over 120 minutes on day 2. Thirty minutes before chemotherapy, premedication consisted of a 5-hydroxytryptamine3(HT3) receptor antagonist. Furthermore, Vitamin C 2g and Vitamin B2 200mg were followed immediately after the chemotherapy. Treatment was administered every 21 days for a maximum of four cycles or until disease progression or unacceptable toxicity.The prophylactic use of a colony-stimulating factor (CFS) was not permitted in the first cycle.
An initial diagnosis of unilateral primary breast cancer without distant metastases, at least 7 months of follow-up information for disease recurrence and death and triple receptor negative for estrogen receptor (ER), progesterone receptor (PR), Her2 were included as pre-treatment evaluation. Moreover tumor size, number of involved axillary lymph nodes (ALN), clinical stage and biomarkers such as Cathepsin-D, P53, nm23, PS2 and PCNA, were recorded as available information for further analysis. In the procedure of neoadjuvant chemotherapy, weekly or biweekly complete blood cell counts, physical examination, electrocardiogram (EKG), liver and rental function tests should be repeated. Tumor size was assessed by magnetic resonance imaging (MRI) every two cycles or when the clinical signs suggested disease progression as well as before the chemotherapy. Tumor response was determined by response evaluation criteria in solid tumors (RECIST). Complete and partial response (CR and PR) should be confirmed on two assessments performed at least four weeks apart.
Study design
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Women aged from 18 to 65 years;
- Histologically or cytologically proven invasive unilateral breast cancer (regardless of the type);
- Initial clinical condition compatible with complete initial resection;
- No residual macro or microscopic tumor after surgical excision;
- Patient presenting one of the following criteria (reviewed before randomization by referent pathologist):
Key exclusion criteria (13 listed)
- Bilateral breast cancer or patient with controlateral DCIS;
- Any metastatic impairment, including homolateral sub-clavicular node involvement,regardless of its type;
- Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);
- Luminal A, Luminal B and Her-2 overexpression
- Any clinically or radiologically suspect and non-explored damage to the controlateral breast;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| docetaxel oxaliplatindocetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2 1 cycle=21 days DO*6 | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2010.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A study testing docetaxel oxaliplatin in people with Triple Negative Local Advanced Breast Cancer, run by Fudan University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Zhimin Shao, MD, PHD (+862164175590 ext. 8708, luona801379@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2010.